ClinicalTrials.gg
Active, not recruitingNCT06206837Updated Sep 30, 2026Results posted

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

A Phase 1/2 interventional study of vepdegestrant and PF-07220060 in Breast Cancer, sponsored by Pfizer. Active, not recruiting at 58 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Updated Sep 30, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing vepdegestrant in Breast Neoplasms — 1 open to participants now, 6 under way, 2 of them phase 3. vepdegestrant · Breast Neoplasms.

Enrollment
5th of 12
71 · median 48
Started
2024
with 1 other
Phase 1/2
5 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
8 of 12
Pfizer

Among the 12 studies testing vepdegestrant in Breast Neoplasms, this one is the 5th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 1/2, and was the 12th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 12 studies testing vepdegestrant in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vepdegestrant

vepdegestrant: first FDA approval 2026 (VEPPANU). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing vepdegestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that:

  • is hard to treat (advanced) and may have spread to other organs (metastatic).
  • is sensitive to hormonal therapy (it is called estrogen receptor positive).
  • is no longer responding to treatments taken before starting this study.

All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until:

  • their cancer is no longer responding, or
  • side effects become too severe. They will have visits at the study clinic about every 4 weeks.
Read the detailed description

C4891026 is a prospective, open-label, multicenter, Phase 1b/2 study to evaluate the safety, antitumor activity, and pharmacokinetic (PK) of vepdegestrant in combination with PF-07220060 in the treatment of participants with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Advanced or Metastatic Breast Cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Proteolysis Targeting Chimera (PROTAC)
  • metastatic breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of breast cancer. At time of enrollment this must not be amenable to surgical resection with curative intent (≥1% ER+ stained cells as per local practice on the most recent tumor - tumor by IHC or in-situ hybridization per ASCO/CAP).
  • prior anticancer therapies: Phase 1b: at least 1 line of SOC for A/MBC; Prior fulvestrant allowed; ≤1 prior chemotherapy line (no antibody-drug conjugates permitted) for A/MBC setting allowed. Phase 2: At least one and maximum 2 lines of ET in A/MBC setting and most recent ET-based regimen for >6 months.

    1, and only 1, prior CDK4/6 inhibitor-based regimen required. Up to 1 prior regimen of cytotoxic chemotherapy (no antibody-drug conjugates permitted) in the A/MBC setting; Prior fulvestrant allowed.

  • Participant with only non- (Phase1b) or at least 1 measurable lesion as defined by v1.1. (Phase2) are eligible.
  • PS = 0 or 1 (Phase1b) ; ≤2 (Phase2)

Exclusion criteria

Exclusion Criteria:

  • visceral crisis at risk of life-threatening complications in the short term.
  • Any condition precluding an adeguate absorption of study interventions.
  • newly diagnosed , or symptomatic central nervous system (CNS) , carcinomatous meningitis, or . Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and for at least 28 days prior to enrollment in the of study.
  • history of any other tumor within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix. Inflammatory breast cancer are excluded
  • impaired cardiovascular function or cardiovascular diseases.
  • concurrent administration of medications, food, or herb supplements that are strong inhibitors/inducers of or UGT2B7, moderate inducers of CYP34 (Phase1b only) and drugs known to predispose to Torsade de Pointes or prolongation.
  • renal impairment, not adequate liver function and/or bone marrow function.
  • known active infection
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    vepdegestrant in combination with PF-07220060

    vepdegestrant administered orally once daily (QD) continuously and PF-07220060 administered orally twice daily (BID) continuously on 28-day cycles

    Drug: vepdegestrant · Drug: PF-07220060

Interventions

  • Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days

    Also known as: ARV-471 / PF07850327

  • Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs): Phase 1b

    Hematological DLT: neutropenic fever; Grade\>=3 thrombocytopenia associated with Grade\>=2(clinically significant)bleeding and Grade4 neutropenia/thrombocytopenia lasting \<7 days. Non-hematological: Grade\>=3 toxicities clinically significant,except those that were not been maximally treated;Grade 2 aspartate aminotransferase(AST), alanine aminotransferase(ALT)/alkaline phosphatase(ALP) levels at baseline as result of liver/bone metastasis,AST,ALT and ALP level\>8\*baseline/AST/ALT \>5\*baseline for\>=14 days; Hy's Law(concomitant ALT/AST elevation of \>=3\*upper limit of normal \[ULN\], total bilirubin elevation\>=2\*ULN without clear alternative etiology); Grade≥3 electrolyte abnormality with clinical sequelae; QTcF prolongation:any Grade\>=3 QT prolongation without clear alternative etiology;any adverse event (AE) attributed to Vepdegestrant and/or PF-07220060 resulting in failure to deliver 75% of doses for either/both agents and any death not clearly due to underlying disease/extraneous causes.

    Time frame: Cycle 1 (28 days)

  2. Percentage of Participants With Confirmed Objective Response (OR) by Derived Investigator Assessment: Phase 2

    OR was defined as best overall response (BOR) of confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis \<10 millimeter \[mm\]). PR was defined as at least a \>=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.

    Time frame: From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related TEAEs: Phase 1b

    AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. Serious adverse event (SAE): any untoward medical occurrence, at any dose met one or more of following criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator.

    Time frame: From the date of first dose of study treatment combination through study completion

  2. Number of Participants With Laboratory Abnormalities: Phase 1b

    Laboratory parameters assessed: hemoglobin, platelets, white blood cells (WBC), absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase.

    Time frame: From the date of first dose of study treatment combination through study completion

  3. Number of Participants With Electrocardiogram (ECG) Abnormalities: Phase 1b

    Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes.

    Time frame: From the date of first dose of study treatment combination through study completion

  4. Percentage of Participants With Confirmed OR by Derived Investigator Assessment: Phase 1b

    OR was defined as BOR of confirmed CR or PR according to RECIST v 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a \>=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.

    Time frame: From the date of first dose of study treatment combination through study completion

  5. Duration of Response (DOR) by Derived Investigator Assessment: Phase 1b

    DoR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: \>=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of \>2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.

    Time frame: From the date of first dose of study treatment combination through study completion

  6. Clinical Benefit Response (CBR) by Derived Investigator Assessment: Phase 1b

    CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis\<10 mm). PR: at least \>=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion.

    Time frame: From the date of first dose of study treatment combination through study completion

  7. Progression Free Survival (PFS) by Derived Investigator Assessment: Phase 1b

    PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.

    Time frame: From the date of first dose of study treatment combination through study completion

  8. Plasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b

    Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.

    Time frame: Cycle 1, Day 8: Pre-dose; Cycle 1 Day 15: Pre-dose, 30 minutes, 1, 2, 4 ,6, 8 and 12 hours post-dose; Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose

  9. Plasma Concentration of PF-07220060: Phase 1b

    Time frame: Pre-dose (0 hour) of Day 8 of Cycle 1; pre-dose (0 hour), 0.5,1,2,4,6,8 and 12 hours post-dose of Day 15 of Cycle 1; Pre-dose (0 hour) and anytime between 4 to 8 hour post-dose of Day 1 and 15 of Cycle 2; Pre-dose (0 hour) of Day 1 of Cycle 3, 5 and 7

  10. Steady State Maximum Observed Plasma Concentration (Cmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b

    Cmax,ss was the steady-state maximum concentration of ARV-471 after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471.

    Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

  11. Cmax,ss of PF-07220060: Phase 1b

    Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

  12. Steady State Time to Maximum Plasma Concentration (Tmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b

    Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471. ARV-473 is an epimer of ARV-471.

    Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

  13. Tmax,ss of PF-07220060: Phase 1b

    Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data.

    Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

  14. Steady State Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b

    AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method.

    Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

  15. AUClast,ss of PF-07220060: Phase 1b

    AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method.

    Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

  16. Apparent Total Clearance (CL/F) of Vepdegestrant (ARV-471): Phase 1b

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

  17. CL/F of PF-07220060: Phase 1b

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

  18. Apparent Volume of Distribution (Vz/F) of PF-07220060: Phase 1b

    Vz/F was calculated as Dose/(AUCinf \* kel). AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

  19. Terminal Half-Life (t1/2) of PF-07220060: Phase 1b

    T1/2 was calculated as loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

  20. DOR by Derived Investigator Assessment: Phase 2

    DOR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: \>=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of \>2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.

    Time frame: From the date of first dose of study treatment combination through study completion

  21. Percentage of Participants With CBR by Derived Investigator Assessment: Phase 2

    CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis\<10 mm). PR: at least \>=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion.

    Time frame: From the date of first dose of study treatment combination through study completion

  22. PFS by Derived Investigator Assessment: Phase 2

    PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.

    Time frame: From the date of first dose of study treatment combination through study completion

  23. Overall Survival (OS): Phase 2

    OS was defined as the time from the date of first dose of study treatment combination to the date of death due to any cause. Participants last known to be alive were censored at the date of last contact. Kaplan-Meier method will be used.

    Time frame: From the date of first dose of study treatment combination through study completion

  24. Number of Participants With TEAEs, TESAEs and Treatment Related TEAEs: Phase 2

    AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. SAE: any untoward medical occurrence, at any dose met one or more of following criteria: death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator.

    Time frame: From the date of first dose of study treatment combination through study completion

  25. Number of Participants With ECG Abnormalities: Phase 2

    Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes.

    Time frame: From the date of first dose of study treatment combination through study completion

  26. Number of Participants With Laboratory Abnormalities: Phase 2

    Laboratory parameters assessed included hemoglobin, platelets, WBC, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, ALT, AST, ALP, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or BUN, creatinine, eGFR, uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase.

    Time frame: From the date of first dose of study treatment combination through study completion

  27. Plasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 2

    Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.

    Time frame: Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose

  28. Plasma Concentration of PF-07220060: Phase 2

    Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.

    Time frame: Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hours post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose

  29. Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA) Plasma Level: Phase 2

    Time frame: Baseline and up to End of Treatment

07

Results

Posted Sep 30, 2026

Participant flow

Phase 1b: Vepdegestrant
Participant flow — Phase 1b: Vepdegestrant
MilestonePhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Started9700
Completed0000
Not completed9700
Withdrew: Adverse event0100
Withdrew: Physician decision1000
Withdrew: Progressive disease5300
Withdrew: Other1000
Withdrew: Ongoing2300
Phase 1b: PF-07220060
Participant flow — Phase 1b: PF-07220060
MilestonePhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Started9700
Completed0000
Not completed9700
Withdrew: Adverse event0100
Withdrew: Physician decision1000
Withdrew: Progressive disease5300
Withdrew: Other1000
Withdrew: Ongoing2300
Phase 2: Vepdegestrant
Participant flow — Phase 2: Vepdegestrant
MilestonePhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Started002728
Completed0000
Not completed002728
Withdrew: Adverse event0001
Withdrew: Progressive disease00912
Withdrew: Withdrawal by subject0010
Withdrew: Global deterioration of health status0010
Withdrew: Other0020
Withdrew: Ongoing001414
Withdrew: Randomized but not treated0001
Phase 2: PF-07220060
Participant flow — Phase 2: PF-07220060
MilestonePhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Started002728
Completed0000
Not completed002728
Withdrew: Adverse event0001
Withdrew: Progressive disease001012
Withdrew: Withdrawal by subject0010
Withdrew: Global deterioration of health status0010
Withdrew: Other0020
Withdrew: Ongoing001314
Withdrew: Randomized but not treated0001

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs): Phase 1b

Hematological DLT: neutropenic fever; Grade\>=3 thrombocytopenia associated with Grade\>=2(clinically significant)bleeding and Grade4 neutropenia/thrombocytopenia lasting \<7 days. Non-hematological: Grade\>=3 toxicities clinically significant,except those that were not been maximally treated;Grade 2 aspartate aminotransferase(AST), alanine aminotransferase(ALT)/alkaline phosphatase(ALP) levels at baseline as result of liver/bone metastasis,AST,ALT and ALP level\>8\*baseline/AST/ALT \>5\*baseline for\>=14 days; Hy's Law(concomitant ALT/AST elevation of \>=3\*upper limit of normal \[ULN\], total bilirubin elevation\>=2\*ULN without clear alternative etiology); Grade≥3 electrolyte abnormality with clinical sequelae; QTcF prolongation:any Grade\>=3 QT prolongation without clear alternative etiology;any adverse event (AE) attributed to Vepdegestrant and/or PF-07220060 resulting in failure to deliver 75% of doses for either/both agents and any death not clearly due to underlying disease/extraneous causes.

Time frame:
Cycle 1 (28 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLTs): Phase 1b
ParticipantsPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Number of Participants With Dose-Limiting Toxicities (DLTs): Phase 1b11
PrimaryPercentage of Participants With Confirmed Objective Response (OR) by Derived Investigator Assessment: Phase 2

OR was defined as best overall response (BOR) of confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis \<10 millimeter \[mm\]). PR was defined as at least a \>=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.

Time frame:
From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)
Reported as:
Number · Percentage of participants
Percentage of Participants With Confirmed Objective Response (OR) by Derived Investigator Assessment: Phase 2
Percentage of participantsPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Percentage of Participants With Confirmed Objective Response (OR) by Derived Investigator Assessment: Phase 218.5 (8.2 to 36.7)22.2 (10.6 to 40.8)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related TEAEs: Phase 1b

AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. Serious adverse event (SAE): any untoward medical occurrence, at any dose met one or more of following criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryNumber of Participants With Laboratory Abnormalities: Phase 1b

Laboratory parameters assessed: hemoglobin, platelets, white blood cells (WBC), absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryNumber of Participants With Electrocardiogram (ECG) Abnormalities: Phase 1b

Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Confirmed OR by Derived Investigator Assessment: Phase 1b

OR was defined as BOR of confirmed CR or PR according to RECIST v 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). PR was defined as at least a \>=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) by Derived Investigator Assessment: Phase 1b

DoR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: \>=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of \>2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryClinical Benefit Response (CBR) by Derived Investigator Assessment: Phase 1b

CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis\<10 mm). PR: at least \>=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryProgression Free Survival (PFS) by Derived Investigator Assessment: Phase 1b

PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryPlasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b

Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.

Time frame:
Cycle 1, Day 8: Pre-dose; Cycle 1 Day 15: Pre-dose, 30 minutes, 1, 2, 4 ,6, 8 and 12 hours post-dose; Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
Reported as:
Mean · Nanogram per milliliter (ng/mL)
Plasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
Nanogram per milliliter (ng/mL)Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
ARV-471: Cycle 1 Day 8 (Pre-dose)375.0 ± 104.99508.3 ± 235.65
ARV-471: Cycle 1 Day 15 (Pre-dose)468.4 ± 164.97567.0 ± 89.601
ARV-471: Cycle 1 Day 15 (0.5-hour Post-dose)476.2 ± 149.9571.8 ± 83.548
ARV-471: Cycle 1 Day 15 (1-hour Post-dose)557.9 ± 192.94593.6 ± 143.79
ARV-471: Cycle 1 Day 15 (2-hour Post-dose)673.4 ± 271.02699.4 ± 153.54
ARV-471: Cycle 1 Day 15 (4-hour Post-dose)924.4 ± 385.02754.8 ± 136.3
ARV-471: Cycle 1 Day 15 (6-hour Post-dose)864.3 ± 311.86735.8 ± 134.9
ARV-471: Cycle 1 Day 15 (8-hour Post-dose)822.1 ± 229.43798.5 ± 307.54
ARV-471: Cycle 1 Day 15 (12-hour Post-dose)772.9 ± 197.54650.6 ± 132.92
ARV-471: Cycle 2 Day 1 (Pre-dose)418.2 ± 203.74482.0 ± 261.75
ARV-471: Cycle 2 Day 1 (4-8 hour Post-dose)875.1 ± 325.671015 ± 611.37
ARV-471: Cycle 2 Day 15 (Pre-dose)376.6 ± 124.07492.0 ± 225.87
ARV-471: Cycle 2 Day 15 (4-8 hour Post-dose)727.4 ± 224.681044 ± 601.31
ARV-471: Cycle 3 Day 1 (Pre-dose)280.4 ± 208.3474.3 ± 168.69
ARV-471: Cycle 5 Day 1 (Pre-dose)234.6 ± 195.5520.3 ± 109.65
ARV-471: Cycle 7 Day 1 (Pre-dose)465.0 ± 348.17562.7 ± 246.13
ARV-473: Cycle 1 Day 8 (Pre-dose)162.5 ± 56.484212.3 ± 105.56
ARV-473: Cycle 1 Day 15 (Pre-dose)191.9 ± 81.727252.2 ± 73.538
ARV-473: Cycle 1 Day 15 (0.5-hour Post-dose)190.8 ± 74.231242.0 ± 54.724
ARV-473: Cycle 1 Day 15 (1-hour Post-dose)196.2 ± 81.734228.2 ± 65.194
ARV-473: Cycle 1 Day 15 (2-hour Post-dose)198.3 ± 81.097235.4 ± 70.515
ARV-473: Cycle 1 Day 15 (4-hour Post-dose)226.8 ± 85.994240.4 ± 67.534
ARV-473: Cycle 1 Day 15 (6-hour Post-dose)234.7 ± 97.739252.2 ± 69.309
ARV-473: Cycle 1 Day 15 (8-hour Post-dose)231.2 ± 94.873274.0 ± 89.971
ARV-473: Cycle 1 Day 15 (12-hour Post-dose)239.8 ± 87.325247.0 ± 75.432
ARV-473: Cycle 2 Day 1 (Pre-dose)182.8 ± 95.3219.4 ± 132.45
ARV-473: Cycle 2 Day 1 (4-8 hour Post-dose)215.3 ± 88.692289.2 ± 173.68
ARV-473: Cycle 2 Day 15 (Pre-dose)161.1 ± 57.394210.8 ± 94.977
ARV-473: Cycle 2 Day 15 (4-8 hour Post-dose)193.7 ± 64.42281.3 ± 136.33
ARV-473: Cycle 3 Day 1 (Pre-dose)124.4 ± 84.322217.4 ± 95.033
ARV-473: Cycle 5 Day 1 (Pre-dose)124.4 ± 89.004242.5 ± 69.869
ARV-473: Cycle 7 Day 1 (Pre-dose)186.4 ± 113.54225.3 ± 95.824
SecondaryPlasma Concentration of PF-07220060: Phase 1b
Time frame:
Pre-dose (0 hour) of Day 8 of Cycle 1; pre-dose (0 hour), 0.5,1,2,4,6,8 and 12 hours post-dose of Day 15 of Cycle 1; Pre-dose (0 hour) and anytime between 4 to 8 hour post-dose of Day 1 and 15 of Cycle 2; Pre-dose (0 hour) of Day 1 of Cycle 3, 5 and 7
Reported as:
Mean · ng/mL
Plasma Concentration of PF-07220060: Phase 1b
ng/mLPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Day 8 Cycle 1 (Pre-dose)460.7 ± 232.49931.3 ± 390.16
Day 15 Cycle 1 (Pre-dose)439.7 ± 203.91742.8 ± 206.47
Day 15 Cycle 1 (0.5 hour Post- dose)510.4 ± 199.78824.5 ± 268.93
Day 15 Cycle 1 (1 hour Post- dose)588.9 ± 249.77915.8 ± 244.79
Day 15 Cycle 1 (2 hour Post- dose)739.6 ± 450.37941.6 ± 196.25
Day 15 Cycle 1 (4 hour Post- dose)698.0 ± 397.07818.2 ± 207.73
Day 15 Cycle 1 (6 hour Post- dose)571.0 ± 290.69641.6 ± 207.47
Day 15 Cycle 1 (8 hour Post- dose)472.9 ± 190.36616.0 ± 285.36
Day 15 Cycle 1 (12 hour Post- dose)412.1 ± 162.65515.3 ± 335.06
Day 1 Cycle 2 (Pre-dose)426.7 ± 216.56697.5 ± 363.98
Day 1 Cycle 2 (4-8 hour Post- dose)744.9 ± 770.091117 ± 656.23
Day 15 Cycle 2 (Pre-dose)330.0 ± 119.7794.6 ± 408.27
Day 15 Cycle 2 (4-8 hour Post- dose)472.3 ± 106.81968.2 ± 518.43
Day 1 Cycle 3 (Pre-dose)276.4 ± 264.85911.5 ± 411.37
Day 1 Cycle 5 (Pre-dose)161.8 ± 156.45926.8 ± 431.03
Day 1 Cycle 7 (Pre-dose)158.1 ± 130.06798.0 ± 537.58
SecondarySteady State Maximum Observed Plasma Concentration (Cmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b

Cmax,ss was the steady-state maximum concentration of ARV-471 after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471.

Time frame:
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Reported as:
Geometric mean · ng/mL
Steady State Maximum Observed Plasma Concentration (Cmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
ng/mLPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
ARV-471938.6 ± 33876.6 ± 43
ARV-473234.6 ± 38278.5 ± 35
SecondaryCmax,ss of PF-07220060: Phase 1b
Time frame:
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Reported as:
Geometric mean · ng/mL
Cmax,ss of PF-07220060: Phase 1b
ng/mLPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Cmax,ss of PF-07220060: Phase 1b699.8 ± 531028 ± 29
SecondarySteady State Time to Maximum Plasma Concentration (Tmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b

Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471. ARV-473 is an epimer of ARV-471.

Time frame:
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Reported as:
Median · Hours
Steady State Time to Maximum Plasma Concentration (Tmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
HoursPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
ARV-4714.08 (3.8 to 10.0)3.98 (1.97 to 7.63)
ARV-4737.97 (3.87 to 10.2)6.02 (2.77 to 10.0)
SecondaryTmax,ss of PF-07220060: Phase 1b

Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data.

Time frame:
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Reported as:
Median · Hours
Tmax,ss of PF-07220060: Phase 1b
HoursPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Tmax,ss of PF-07220060: Phase 1b2.05 (1.05 to 5.97)1.42 (0.683 to 2.1)
SecondarySteady State Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b

AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method.

Time frame:
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Reported as:
Geometric mean · Nanogram*hour per milliliter (ng*hr/mL)
Steady State Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
Nanogram*hour per milliliter (ng*hr/mL)Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
ARV-4717505 ± 337580 ± 31
ARV-4732100 ± 382544 ± 33
SecondaryAUClast,ss of PF-07220060: Phase 1b

AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method.

Time frame:
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Reported as:
Geometric mean · ng*hr/mL
AUClast,ss of PF-07220060: Phase 1b
ng*hr/mLPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
AUClast,ss of PF-07220060: Phase 1b5269 ± 487028 ± 34
SecondaryApparent Total Clearance (CL/F) of Vepdegestrant (ARV-471): Phase 1b

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Reported as:
Geometric mean · Liters per hour (L/hr)
Apparent Total Clearance (CL/F) of Vepdegestrant (ARV-471): Phase 1b
Liters per hour (L/hr)Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Apparent Total Clearance (CL/F) of Vepdegestrant (ARV-471): Phase 1b12.75 ± 2912.02 ± 30
SecondaryCL/F of PF-07220060: Phase 1b

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Reported as:
Geometric mean · L/hr
CL/F of PF-07220060: Phase 1b
L/hrPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
CL/F of PF-07220060: Phase 1b—51.7
SecondaryApparent Volume of Distribution (Vz/F) of PF-07220060: Phase 1b

Vz/F was calculated as Dose/(AUCinf \* kel). AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vz/F) of PF-07220060: Phase 1b
LitersPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Apparent Volume of Distribution (Vz/F) of PF-07220060: Phase 1b—295
SecondaryTerminal Half-Life (t1/2) of PF-07220060: Phase 1b

T1/2 was calculated as loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Reported as:
Mean · Hours
Terminal Half-Life (t1/2) of PF-07220060: Phase 1b
HoursPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Terminal Half-Life (t1/2) of PF-07220060: Phase 1b—3.96
SecondaryDOR by Derived Investigator Assessment: Phase 2

DOR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: \>=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of \>2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryPercentage of Participants With CBR by Derived Investigator Assessment: Phase 2

CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis\<10 mm). PR: at least \>=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryPFS by Derived Investigator Assessment: Phase 2

PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryOverall Survival (OS): Phase 2

OS was defined as the time from the date of first dose of study treatment combination to the date of death due to any cause. Participants last known to be alive were censored at the date of last contact. Kaplan-Meier method will be used.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryNumber of Participants With TEAEs, TESAEs and Treatment Related TEAEs: Phase 2

AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. SAE: any untoward medical occurrence, at any dose met one or more of following criteria: death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryNumber of Participants With ECG Abnormalities: Phase 2

Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryNumber of Participants With Laboratory Abnormalities: Phase 2

Laboratory parameters assessed included hemoglobin, platelets, WBC, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, ALT, AST, ALP, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or BUN, creatinine, eGFR, uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase.

Time frame:
From the date of first dose of study treatment combination through study completion

Results for this outcome have not been posted.

SecondaryPlasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 2

Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.

Time frame:
Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
Reported as:
Mean · ng/mL
Plasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 2
ng/mLPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
ARV-471: Cycle 1 Day 15 (Pre-dose)449.4 ± 178.42478.4 ± 191.59
ARV-471: Cycle 1 Day 15 (4-8 hour Post-dose)886.8 ± 321.78895.8 ± 339.54
ARV-471: Cycle 2 Day 1 (Pre-dose)433.3 ± 164.75403.3 ± 184.21
ARV-471: Cycle 2 Day 1 (4-8 hour Post-dose)795.6 ± 322.46793.1 ± 303.95
ARV-471: Cycle 2 Day 15 (Pre-dose)433.6 ± 185.66477.8 ± 232.24
ARV-471: Cycle 2 Day 15 (4-8 hour Post-dose)848.2 ± 280.9904.2 ± 419.08
ARV-471: Cycle 3 Day 1 (Pre-dose)414.9 ± 180.37435.9 ± 194.19
ARV-471: Cycle 5 Day 1 (Pre-dose)373.1 ± 233.75465.8 ± 138.87
ARV-471: Cycle 7 Day 1 (Pre-dose)427.6 ± 195.86487.4 ± 122.95
ARV-473: Cycle 1 Day 15 (Pre-dose)186.6 ± 75.807202.3 ± 84.462
ARV-473: Cycle 1 Day 15 (4-8 hour Post-dose)222.9 ± 91.726230.4 ± 93.664
ARV-473: Cycle 2 Day 1 (Pre-dose)184.0 ± 74.338176.4 ± 88.319
ARV-473: Cycle 2 Day 1 (4-8 hour Post-dose)208.0 ± 88.597200.1 ± 87.735
ARV-473: Cycle 2 Day 15 (Pre-dose)180.3 ± 83.956195.3 ± 82.348
ARV-473: Cycle 2 Day 15 (4-8 hour Post-dose)223.8 ± 81.906217.3 ± 101.9
ARV-473: Cycle 3 Day 1 (Pre-dose)176.9 ± 77.298192.9 ± 91.457
ARV-473: Cycle 5 Day 1 (Pre-dose)155.9 ± 87.197192.5 ± 52.849
ARV-473: Cycle 7 Day 1 (Pre-dose)185.6 ± 80.085207.2 ± 46.089
SecondaryPlasma Concentration of PF-07220060: Phase 2

Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.

Time frame:
Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hours post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
Reported as:
Mean · ng/mL
Plasma Concentration of PF-07220060: Phase 2
ng/mLPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Cycle 1 Day 15 (Pre-dose)485.2 ± 292.69939.5 ± 583.9
Cycle 1 Day 15 (4-8 hour Post-dose)481.5 ± 163.821194 ± 506.16
Cycle 2 Day 1 (Pre-dose)415.1 ± 227.66768.3 ± 491.03
Cycle 2 Day 1 (4-8 hour Post-dose)491.2 ± 160.38828.4 ± 426.88
Cycle 2 Day 15 (Pre-dose)395.3 ± 165.3833.7 ± 517.24
Cycle 2 Day 15 (4-8 hour Post-dose)467.2 ± 205.24921.0 ± 362.77
Cycle 3 Day 1 (Pre-dose)421.0 ± 216.97724.7 ± 444.27
Cycle 5 Day 1 (Pre-dose)379.2 ± 235.37908.7 ± 606.3
Cycle 7 Day 1 (Pre-dose)414.6 ± 294.59664.6 ± 212.21
SecondaryChange From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA) Plasma Level: Phase 2
Time frame:
Baseline and up to End of Treatment

Results for this outcome have not been posted.

Adverse events

Collected over From Day 1 of dosing up to 28 days after last dose "maximum up to 16.5 months for Phase 1b and 10.5 months for Phase 2 as maximum treatment exposure was 15.5 months and 9.5 months for Phase 1b and 2 respectively". Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID1/9 (11.1%)4/9 (44.4%)9/9 (100%)
Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID0/7 (0%)1/7 (14.3%)7/7 (100%)
Phase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BID2/27 (7.4%)3/27 (11.1%)27/27 (100%)
Phase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID2/27 (7.4%)5/27 (18.5%)27/27 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
Cardiac failureCardiac disorders0/91/70/270/27
CellulitisInfections and infestations1/90/70/270/27
PneumoniaInfections and infestations1/90/70/270/27
Urinary tract infectionInfections and infestations1/90/70/270/27
FallInjury, poisoning and procedural complications1/90/70/270/27
HypophagiaMetabolism and nutrition disorders1/90/70/270/27
NephrolithiasisRenal and urinary disorders1/90/70/270/27
DiarrhoeaGastrointestinal disorders0/90/70/271/27
Small intestinal obstructionGastrointestinal disorders0/90/71/270/27
StomatitisGastrointestinal disorders0/90/70/271/27
Most frequent other events
Showing 10 of 119
Most frequent other events
EventPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BID
DiarrhoeaGastrointestinal disorders1/94/76/2714/27
Neutrophil count decreasedInvestigations3/94/79/2715/27
NauseaGastrointestinal disorders2/91/78/2712/27
ArthralgiaMusculoskeletal and connective tissue disorders4/90/76/274/27
FatigueGeneral disorders3/93/79/277/27
PruritusSkin and subcutaneous tissue disorders2/93/73/271/27
CoughRespiratory, thoracic and mediastinal disorders0/91/710/272/27
VomitingGastrointestinal disorders3/91/73/275/27
White blood cell count decreasedInvestigations3/92/76/279/27
Electrocardiogram QT prolongedInvestigations2/91/78/271/27

Baseline characteristics

Safety analysis set included all enrolled participants assigned to study intervention and who took at least 1 dose of either vepdegestrant or PF-07220060 study intervention.

Age, Continuous
Age, Continuous(Years)Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDTotal
Mean60.1 ± 8.6271.7 ± 10.6458.8 ± 12.2857.4 ± 11.2659.7 ± 11.84
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDTotal
Female97262769
Male00101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDTotal
Hispanic or Latino215210
Not Hispanic or Latino66202355
Unknown or Not Reported10225
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 1b: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 100 mg BIDPhase 2: Vepdegestrant 200 mg QD + PF-07220060 300 mg BIDTotal
American Indian or Alaska Native00000
Asian339722
Native Hawaiian or Other Pacific Islander00000
Black or African American00101
White64151843
More than one race00000
Unknown or Not Reported00224
08

Study locations

58 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Sep 2025, 18 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 18 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → May 2027, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Jan 16, 2024
StartActual
Feb 19, 2024
Primary completionActual
Sep 5, 2025
CompletionEst.
May 25, 2027was Sep 2026
Results first posted
Sep 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 30, 2026
Sites
1 site added, 1 site removed
Show site
  • Clinical and Translational Research Unit (CTRU) · Palo Alto, United States
Show 1 removed
  • Stanford Women's Cancer Center · Palo Alto, United States
Sep 30, 2026
Study completion
Sep 7, 2026→May 25, 2027
Sep 30, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPhase 1b: Number of Participants With Dose -Limiting Toxicities (DLTs): Phase 1bTime frame: 28 days → Cycle 1 (28 days)
  • EditedPhase 2: Percentage of Participants With Confirmed Objective Response (OR) by investigator assessmentDerived Investigator Assessment: Phase 2Time frame: Up to approximately 1 year → From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)
Sep 30, 2026
Documents
Secondary outcomes
3 edited, 26 added, 1 removed, 13 more
What changed in the outcomes
  • EditedPhase 1b and Phase 2: Duration of Response (DOR) by investigator assessment.Derived Investigator Assessment: Phase 1bTime frame: Up to approximately 1 year → From the date of first dose of study treatment combination through study completion
  • EditedPhase 1b and Phase2: Percentage of participants with Clinical Benefit ResponseParticipants With Confirmed OR by investigator assessment.Derived Investigator Assessment: Phase 1bTime frame: Up to approximately 1 year → From the date of first dose of study treatment combination through study completion
  • EditedPhase 1b and Phase 2: Progression Free Survival (PFS) by investigator assessment.Derived Investigator Assessment: Phase 1bTime frame: Up to approximately 1 year → From the date of first dose of study treatment combination through study completion
  • AddedNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related TEAEs: Phase 1bTime frame: From the date of first dose of study treatment combination through study completion
  • AddedNumber of Participants With Laboratory Abnormalities: Phase 1bTime frame: From the date of first dose of study treatment combination through study completion
  • AddedNumber of Participants With Electrocardiogram (ECG) Abnormalities: Phase 1bTime frame: From the date of first dose of study treatment combination through study completion
  • AddedClinical Benefit Response (CBR) by Derived Investigator Assessment: Phase 1bTime frame: From the date of first dose of study treatment combination through study completion
  • AddedPlasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1bTime frame: Cycle 1, Day 8: Pre-dose; Cycle 1 Day 15: Pre-dose, 30 minutes, 1, 2, 4 ,6, 8 and 12 hours post-dose; Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
  • AddedPlasma Concentration of PF-07220060: Phase 1bTime frame: Pre-dose (0 hour) of Day 8 of Cycle 1; pre-dose (0 hour), 0.5,1,2,4,6,8 and 12 hours post-dose of Day 15 of Cycle 1; Pre-dose (0 hour) and anytime between 4 to 8 hour post-dose of Day 1 and 15 of Cycle 2; Pre-dose (0 hour) of Day 1 of Cycle 3, 5 and 7
  • AddedSteady State Maximum Observed Plasma Concentration (Cmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
  • AddedCmax,ss of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
  • AddedSteady State Time to Maximum Plasma Concentration (Tmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
  • AddedTmax,ss of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
  • AddedSteady State Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
  • AddedAUClast,ss of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
  • AddedApparent Total Clearance (CL/F) of Vepdegestrant (ARV-471): Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
  • AddedCL/F of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
  • AddedApparent Volume of Distribution (Vz/F) of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
  • AddedTerminal Half-Life (t1/2) of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
  • AddedDOR by Derived Investigator Assessment: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
  • AddedPercentage of Participants With CBR by Derived Investigator Assessment: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
  • AddedPFS by Derived Investigator Assessment: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
  • AddedOverall Survival (OS): Phase 2Time frame: From the date of first dose of study treatment combination through study completion
  • AddedNumber of Participants With TEAEs, TESAEs and Treatment Related TEAEs: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
  • AddedNumber of Participants With ECG Abnormalities: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
  • AddedNumber of Participants With Laboratory Abnormalities: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
  • AddedPlasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 2Time frame: Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
  • AddedPlasma Concentration of PF-07220060: Phase 2Time frame: Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hours post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
  • AddedChange From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA) Plasma Level: Phase 2Time frame: Baseline and up to End of Treatment
  • RemovedPhase 1b and Phase 2: Evaluation of Safety of Vepdegestrant in combination with PF-07220060 (number of participants experiencing any AE, SAE, treatment-related AE and treatment-related SAE)Time frame: First study drug dose through a minimum of 28 Days After Last study drug administration
  • …and 13 more, on the record history on ClinicalTrials.gov ↗
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Clinical and Translational Research Unit (CTRU) · Palo Alto, United States
    Show 1 removed
    • Stanford Women's Cancer Center · Palo Alto, United States
    Study completion Sep 7, 2026→May 25, 2027
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPhase 1b: Number of Participants With Dose -Limiting Toxicities (DLTs): Phase 1bTime frame: 28 days → Cycle 1 (28 days)
    • EditedPhase 2: Percentage of Participants With Confirmed Objective Response (OR) by investigator assessmentDerived Investigator Assessment: Phase 2Time frame: Up to approximately 1 year → From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)
    Secondary outcomes 3 edited, 26 added, 1 removed, 13 more
    What changed in the outcomes
    • EditedPhase 1b and Phase 2: Duration of Response (DOR) by investigator assessment.Derived Investigator Assessment: Phase 1bTime frame: Up to approximately 1 year → From the date of first dose of study treatment combination through study completion
    • EditedPhase 1b and Phase2: Percentage of participants with Clinical Benefit ResponseParticipants With Confirmed OR by investigator assessment.Derived Investigator Assessment: Phase 1bTime frame: Up to approximately 1 year → From the date of first dose of study treatment combination through study completion
    • EditedPhase 1b and Phase 2: Progression Free Survival (PFS) by investigator assessment.Derived Investigator Assessment: Phase 1bTime frame: Up to approximately 1 year → From the date of first dose of study treatment combination through study completion
    • AddedNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related TEAEs: Phase 1bTime frame: From the date of first dose of study treatment combination through study completion
    • AddedNumber of Participants With Laboratory Abnormalities: Phase 1bTime frame: From the date of first dose of study treatment combination through study completion
    • AddedNumber of Participants With Electrocardiogram (ECG) Abnormalities: Phase 1bTime frame: From the date of first dose of study treatment combination through study completion
    • AddedClinical Benefit Response (CBR) by Derived Investigator Assessment: Phase 1bTime frame: From the date of first dose of study treatment combination through study completion
    • AddedPlasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1bTime frame: Cycle 1, Day 8: Pre-dose; Cycle 1 Day 15: Pre-dose, 30 minutes, 1, 2, 4 ,6, 8 and 12 hours post-dose; Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
    • AddedPlasma Concentration of PF-07220060: Phase 1bTime frame: Pre-dose (0 hour) of Day 8 of Cycle 1; pre-dose (0 hour), 0.5,1,2,4,6,8 and 12 hours post-dose of Day 15 of Cycle 1; Pre-dose (0 hour) and anytime between 4 to 8 hour post-dose of Day 1 and 15 of Cycle 2; Pre-dose (0 hour) of Day 1 of Cycle 3, 5 and 7
    • AddedSteady State Maximum Observed Plasma Concentration (Cmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
    • AddedCmax,ss of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
    • AddedSteady State Time to Maximum Plasma Concentration (Tmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
    • AddedTmax,ss of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
    • AddedSteady State Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
    • AddedAUClast,ss of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
    • AddedApparent Total Clearance (CL/F) of Vepdegestrant (ARV-471): Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
    • AddedCL/F of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
    • AddedApparent Volume of Distribution (Vz/F) of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
    • AddedTerminal Half-Life (t1/2) of PF-07220060: Phase 1bTime frame: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
    • AddedDOR by Derived Investigator Assessment: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
    • AddedPercentage of Participants With CBR by Derived Investigator Assessment: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
    • AddedPFS by Derived Investigator Assessment: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
    • AddedOverall Survival (OS): Phase 2Time frame: From the date of first dose of study treatment combination through study completion
    • AddedNumber of Participants With TEAEs, TESAEs and Treatment Related TEAEs: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
    • AddedNumber of Participants With ECG Abnormalities: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
    • AddedNumber of Participants With Laboratory Abnormalities: Phase 2Time frame: From the date of first dose of study treatment combination through study completion
    • AddedPlasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 2Time frame: Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
    • AddedPlasma Concentration of PF-07220060: Phase 2Time frame: Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hours post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
    • AddedChange From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA) Plasma Level: Phase 2Time frame: Baseline and up to End of Treatment
    • RemovedPhase 1b and Phase 2: Evaluation of Safety of Vepdegestrant in combination with PF-07220060 (number of participants experiencing any AE, SAE, treatment-related AE and treatment-related SAE)Time frame: First study drug dose through a minimum of 28 Days After Last study drug administration
    • …and 13 more, on the record history on ClinicalTrials.gov ↗
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06206837
Lead sponsor
Pfizer
Collaborators
Arvinas Estrogen Receptor, Inc.
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
Feb 19, 2024
Primary completion
Sep 5, 2025
Completion
May 25, 2027 (estimated)
Results posted
Sep 30, 2026
Last update
Sep 30, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vepdegestrant · Atirmociclib

Start the discussion